A recent target of anti‐lung cancer treatment has been immune checkpoint inhibitors, including inhibitors of programmed cell death 1 (PD‐1) and programmed cell death 1‐ligand 1 (PD‐L1). Here, PDCD1 is linked to lung carcinoma.